ClinicalTrials.gg
RecruitingNCT06023602Updated Sep 19, 2025

Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone(GnRH)Antagonist Protocol in Women Undergoing IVF

An interventional study of Generic cetrorelix acetate and Reference cetrorelix acetate in Infertility, sponsored by Northwest Women's and Children's Hospital, Xi'an, Shaanxi. Recruiting at 1 site in China. Open to female participants aged 20 Years to 42 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by Northwest Women's and Children's Hospital, Xi'an, Shaanxi · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,338
Allocation
Randomized
Ages
20 Years to 42 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing cetrorelix in Infertility — 1 open to participants now, 1 under way, none of them phase 3. cetrorelix · Infertility.

Planned enrollment
Largest of 17
1,338 · median 99
Started
2024
the only one that year
No phase
5 of 17
1 open now
Registered
17th of 17
by date
Lead sponsor
1 of 17
Northwest Women's and Children's Hospital, Xi'an, Shaanxi

Among the 17 studies testing cetrorelix in Infertility, this one has the largest planned enrollment, is the only one that started in 2024, is one of 5 with no phase, and was the 17th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 17 studies testing cetrorelix in Infertility is open now, in 1 country.

By country, each count listing its studies:

About cetrorelix

cetrorelix: first FDA approval 2000 (CETROTIDE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 20 Years to 42 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing cetrorelix in Infertility, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the clinical outcomes using different cetrorelix acetate in the context of a GnRH antagonist protocol for ovarian stimulation in women undergoing IVF or intracytoplasmic sperm injection(ICSI) treatment.The main question it aims to answer is whether the generic cetrorelix acetate is non-inferior to the reference product in the GnRH antagonist based protocol for women undergoing IVF. Ovarian stimulation was achieved by several types of follicle-stimulating hormone(FSH) or by FSH combined with luteinizing hormone activity. Daily dose of generic cetrorelix acetate (0.25 mg SC) or original cetrorelix acetate (0.25 mg SC) will be administered when the lead follicle was 14 mm. When more than two follicles reached 17 mm, oocyte maturation was triggered with 250 mcg of recombinant human chorionic gonadotropin.

03

Conditions studied

  • Infertility

Browse trials for

04

Who can participate

Ages eligible
20 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infertile couples plan to undergo IVF / ICSI pregnancy treatment into screening procedures and clinical study

    1. All subjects should sign the form
    2. Infertile women \<43 years old
    3. With flexible GnRH antagonist

Exclusion criteria

Exclusion Criteria:

  • Subjects could not enter the study if they meet any one of the following criteria

    1. Preimplantation Genetic Testing (PGT)
    2. Untreated hydrosalpinges, moderate or severe endometriosis, recurrent spontaneous miscarriage, endometrial pathology, uterine malformations, etc
    3. Endocrine diseases (such as hyperthyroidism, hyperprolactinemia, etc.) or other systemic disease and other systemic diseases (such as hypertension, diabetes, etc.).
    4. Other factors were considered inappropriate by the investigator to participate, or assisted reproductive technology/pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,338 participants (estimated)

Study arms

  • Experimental
    Generic cetrorelix acetate

    Drug: Generic cetrorelix acetate

  • Active comparator
    Reference cetrorelix acetate

    Drug: Reference cetrorelix acetate

Interventions

  • DrugCetrorelixStudies of CetrorelixCetrorelix pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Generic cetrorelix acetate (0.25 mg SC)

  • DrugReference cetrorelix acetate

    reference cetrorelix acetate (0.25 mg SC)

06

What researchers measure

Primary outcomes

  1. Cumulative live birth rate

    For the first live birth (gestation≥ 24 weeks) in one in vitro fertilization/intracytoplasmic sperm injection egg retrieval cycle (fresh and frozen-thawed embryo transfer cycle)

    Time frame: Through study completion, an average of 18 months

07

Study locations

1 of 1 sites recruiting
  • He Cai
    Xi'an, None Selected, China
    Recruiting
08

References and documents

Publications

  • Dovey S, McIntyre K, Jacobson D, Catov J, Wakim A. Is a premature rise in luteinizing hormone in the absence of increased progesterone levels detrimental to pregnancy outcome in GnRH antagonist in vitro fertilization cycles. Fertil Steril. 2011 Sep;96(3):585-9. doi: 10.1016/j.fertnstert.2011.06.042. Epub 2011 Jul 20. PubMed 21774931 ↗
  • Liu X, Wen W, Wang T, Tian L, Li N, Sun T, Wang T, Zhou H, Zhang N, Qu P, Mol BW, Li W, Shi J. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Hum Reprod. 2022 Jul 30;37(8):1806-1815. doi: 10.1093/humrep/deac113. PubMed 35595197 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2025, 21 months after the start.

Of 385 non-industry interventional studies with no phase under Infertility, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 21 months is below that.

Counting every sponsor, half of 415 studies reached it within 24 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2023
First posted
Sep 5, 2023
StartActual
Feb 27, 2024
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 1, 2025
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06023602
Lead sponsor
Northwest Women's and Children's Hospital, Xi'an, Shaanxi
Responsible party
He Cai (Principal Investigator, Northwest Women's and Children's Hospital, Xi'an, Shaanxi) — Principal investigator
First posted
Sep 5, 2023
Start date
Feb 27, 2024
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Sep 19, 2025

Study contacts

HE CAI, Doctor
Contact
caihe@bjmu.edu.cn
+8613581613908
Juanzi Shi, Doctor
Contact
shijuanziart@126.com
+18602991568

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetrorelix

Start the discussion